SP
Spero Therapeutics, Inc.
SPRO · NASDAQ
$1.17 -2.50% (-$0.03)
1M -4.88%
Market Cap $67.7M
P/E Ratio 9.18x
Div. Yield -
ROE 16.17%
Piotroski F-Score Moderate
6/9Valuation
99 /100
Cheap P/FCF 3.46x
P/S 1.58x
P/B 1.53x
Growth
42 /100
Stable Book val. growth 8.06%
Rev. growth 7.06%
FCF growth N/A
Profitability
87 /100
Strong Net margin 17.18%
Op. margin 14.02%
FCF margin 45.57%
Quality
75 /100
Excellent ROE 16.17%
ROA 13.99%
Asset turnover 0.81x
Debt
100 /100
Low Current ratio 6.12x
Net debt/EBITDA -6.33x
Debt/Equity 0.05x
Stability
12 /100
Unstable Rev. volatility 83.77%
EPS volatility 299.71%
Profitable years 1
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na SPRO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Esther Rajavelu
Employees
25
Headquarters
Cambridge
Nadcházející události
12 LIS
Earnings
Upcoming earnings report